Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4482 in Non-Hospitalized Adults with COVID-19
2020-003368-24Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing MK-4482 with Placebo (2 arms). Primary endpoint: Percentage of participants who are hospitalized and/or die. Started Sep 2020; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003368-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003368-24.